Terms: = Prostate cancer AND MNX1, HB9, 3110, ENSG00000130675, P50219, HLXB9 AND Treatment
4 results:
1. Stereotactic Pelvic Reirradiation for Locoregional cancer Relapse.
Kinj R; Doyen J; Hannoun-Lévi JM; Naghavi AO; Chand ME; Baudin G; Ferrero JM; François E; Evesque L; Borchiellini D; Benezery K; Bondiau PY
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e15-e21. PubMed ID: 32641243
[TBL] [Abstract] [Full Text] [Related]
2. Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.
Fuller D; Wurzer J; Shirazi R; Bridge S; Law J; Crabtree T; Mardirossian G
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):291-299. PubMed ID: 31629838
[TBL] [Abstract] [Full Text] [Related]
3. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
[TBL] [Abstract] [Full Text] [Related]
4. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells.
Reile H; Armatis PE; Schally AV
Prostate; 1994 Jul; 25(1):29-38. PubMed ID: 8022709
[TBL] [Abstract] [Full Text] [Related]